Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16850
Country/Region: Nigeria
Year: 2016
Main Partner: AIDS Prevention Initiative in Nigeria, LTD
Main Partner Program: Nigeria
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $15,933,832 Additional Pipeline Funding: $4,225,006

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $4,316,614
Care: Orphans and Vulnerable Children (HKID) $3,509,951
Care: TB/HIV (HVTB) $437,994
Care: Pediatric Care and Support (PDCS) $684,117
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,843,378
Treatment: Adult Treatment (HTXS) $4,801,346
Treatment: Pediatric Treatment (PDTX) $340,432
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 844
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 393
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 844
GEND_GBV Number of people receiving post-GBV care 2017 1,237
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 35,770
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 27,675
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 619,068
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 381,901
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,064,414
HTS_TST Service Delivery Point (Community): Homebased testing 2017 9,547
HTS_TST Service Delivery Point (Community): Index testing 2017 28,644
HTS_TST Service Delivery Point (Community): Mobile testing 2017 133,670
HTS_TST Service Delivery Point (Community): Other 2017 19,096
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,504
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,504
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 780
HTS_TST Service Delivery Point (Facility): Other PITC 2017 82
HTS_TST Service Delivery Point (Facility): Outpatient 2017 436,232
HTS_TST Service Delivery Point (Facility): Pediatric 2017 58,879
HTS_TST Service Delivery Point (Facility): PMTCT 2017 192,971
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 17,951
HTS_TST Service Delivery Point (Facility): VCT 2017 163,554
HTS_TST Sum of Aggregated Age/Sex <15 2017 63,445
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 1,000,969
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 1,064,414
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,027
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 823
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 18,102
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 9,281
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 21
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 23
LAB_PT CD4: Number of laboratories that perform this testing 2017 23
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 3
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 28
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 31
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 31
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 3
OVC_SERV Age/Sex: 18+ Female 2017 4,079
OVC_SERV Age/Sex: 18+ Male 2017 3,900
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 35,090
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 34,907
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 77,976
OVC_SERV Sum of Age/Sex disaggregates 2017 7,979
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,448
PMTCT_ART New on ART 2017 3,922
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 192,971
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,370
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 2,000
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 36
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 55
PMTCT_EID Sum of Infant Age disaggregates 2017 5,370
PMTCT_STAT By: Known positives at entry 2017 3,313
PMTCT_STAT By: Number of new positives identified 2017 2,336
PMTCT_STAT Number of new ANC and L&D clients 2017 203,126
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 192,971
PMTCT_STAT Sum of Positives Status disaggregates 2017 5,649
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 23
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 459
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 20
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 415
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,019
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 917
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,124
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 1,918
TB_SCREENDX Screen Result: Screened Positive for TB 2017 2,364
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 72,094
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 34,410
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,418
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,914
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 109,836
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 93
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,101
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 147
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,209
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 5,042
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 5,599
TX_CURR Aggregated Age/Sex: <15 Female 2017 2,738
TX_CURR Aggregated Age/Sex: <15 Male 2017 2,577
TX_CURR Aggregated Age/Sex: 15+ Female 2017 57,426
TX_CURR Aggregated Age/Sex: 15+ Male 2017 23,292
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 86,033
TX_CURR Sum of Aggregated Age/Sex <15 2017 5,315
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 80,718
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 86,033
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,074
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 945
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 13,609
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 12,063
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 27,691
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 27,691
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 86,034
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 77,430
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,523
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,661
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 53,640
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 20,606
TX_PVLS Numerator: Indication: Routine 2017 61,941
TX_PVLS Numerator: Indication: Targeted 2017 15,489
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,690
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,846
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 59,601
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 22,897
TX_PVLS_den Denominator: Indication: Routine 2017 68,826
TX_PVLS_den Denominator: Indication: Targeted 2017 17,208
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 685
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 762
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 23,470
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9,039
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 33,956
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 39,947
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 813
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 853
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 27,528
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 10,753
Cross Cutting Budget Categories and Known Amounts Total: $1,266,561
Food and Nutrition: Policy, Tools, and Service Delivery $30,000
Food and Nutrition: Commodities $51,349
Economic Strengthening $239,628
Education $10,270
Gender: Gender Based Violence (GBV) $747,810
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $145,110
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Water $42,394